Numis Securities Ltd reiterated their buy rating on shares of Ergomed PLC (LON:ERGO) in a research note issued to investors on Tuesday morning. The brokerage currently has a GBX 267 ($3.31) price objective on the stock.

ERGO has been the topic of several other research reports. Stifel Nicolaus reaffirmed a buy rating and set a GBX 271 ($3.36) price target on shares of Ergomed PLC in a research note on Friday, September 2nd. N+1 Singer lifted their price target on shares of Ergomed PLC from GBX 263 ($3.26) to GBX 265 ($3.29) and gave the stock a buy rating in a research note on Friday, October 21st.

Shares of Ergomed PLC (LON:ERGO) opened at 144.50 on Tuesday. The stock’s market capitalization is GBX 44.96 million. Ergomed PLC has a one year low of GBX 117.00 and a one year high of GBX 172.00. The stock has a 50 day moving average of GBX 125.69 and a 200-day moving average of GBX 125.62.

COPYRIGHT VIOLATION NOTICE: This piece was reported by Financial Market News and is the sole property of of Financial Market News. If you are reading this piece on another site, it was copied illegally and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be accessed at http://www.financial-market-news.com/ergomed-plc-ergo-receives-buy-rating-from-numis-securities-ltd/1210508/.

About Ergomed PLC

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with MarketBeat.com's FREE daily email newsletter.